Price (delayed)
$4.1
Market cap
$232.75M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.99
Enterprise value
$220.4M
Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on
There are no recent dividends present for DSGN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.